glp-1 news Prescriptions Quadruple Since 2021 Alongside Decline In Obesity Crackdown on bootleg GLP-1 drugs

This review aims to summarize the available evidence on this topic

Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp

doi: 10.7759/cureus.77725 70 VoorsAAAngermannCETeerlinkJRCollinsSPKosiborodMBiegusJet al

Using propensity score weighting, the populations were adjusted for differences in baseline spending, health care utilization, age, sex, comorbidities, and smoking status

These include decreased urination or dark-colored urine, dizziness or lightheadedness, extreme thirst and dry mouth, or unusual tiredness and weakness